This combinatory approach has shown promise in preclinical models and early-phase clinical trials, suggesting that LAG-3 inhibitors may provide a complementary mechanism to enhance the effectiveness of existing ICIs in treating melanoma and other cancers. Here, LAG3 is linked to melanoma.